Group IV showed the second highest incidence of transient pyrexia (≥38°C), transient dysphagia and/or retrosternal pain, ulceration, and the third highest incidence of rebleeding. Esophageal perforation or stricture, chest empyema, and pericardial effusion or pipeline varices didn’t occur in any patients of the different study groups. Fundal varices developed in two patients in group I and one in group II, and were successfully treated with endoscopic injection of N-butyl-2-cyanoacrylate

(Histoacryl blue). Recurrence was defined as the appearance of new vascularization over previously sclerosed veins. The recurrence rate was 14% in group I, 28% in group II, 2% in group III and 4% in group IV. The highest recurrence rate of esophageal varices after eradication in each Dinaciclib cost group during the follow up was detected in group II, while the lowest rate was in group III (Table 2). Recurrence rate of esophageal varices after eradication in splenectomized patients occurred Selleck LY294002 within a period ranging from 1 month to 17 months with a total incidence of 15% in splenectomized patients and 10.7% in non-splenectomized patients (Table 3) without any significant difference. No interval bleed before eradication of varices was recorded in any of the studied groups. A higher mortality incidence was detected in group I (18%) and II (12%) than in groups III (8%) and IV (8%) (Table 2); however no definite

explanation for this variety could be found (Fig. 1). A comparison of the number of therapeutic sessions between different study groups showed a mean of 6 + 0.98 in group I, 3.7 + 0.46 in group II, 2.18 + 0.39 in group III and 4.6 + 0.7 in group IV with a significant difference between all studied groups. Group III underwent significantly fewer sessions than the other groups (Fig. 2). The follow-up incidence until complete variceal eradication did not differ significantly between the groups (Fig. 3). The cost in Egyptian pounds MCE for variceal eradication in the different groups, without the fee for staying in hospital, was 540 ± 67 in group I, 1680 ± 530 in group II, 1220 ± 470 in group III and 3680 ± 850

in group IV with a significant difference among all the groups. This study included 200 patients with bleeding esophageal varices; they were randomly divided into four groups (I, II, III and IV). Comparing the therapeutic results of the sclerotherapy group (Group I) and the band ligation group (Group II): we found a lower incidence of treatment-related complications in group II. This was in accordance with Nakase et al.14 who reported a deterioration in liver function in the form of elevated AST, ALT, and bilirubin in patients who underwent sclerotherapy but not band ligation. Similar results were reported by Barosum et al.15 and Mastuda et al.16 This effect was suggested to be due to hemolysis or direct hepatocyte damage that may be caused by ethanolamine oleate.